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Tumours are highly complex tissues composed of carcinoma cells and surrounding stroma, which
is constructed by various different types of mesenchymal cells and an extracellular matrix (ECM).
Carcinoma-associated ﬁbroblasts (CAFs), which consist of both ﬁbroblasts and myoﬁbroblasts, are fre-
quently observed in the stroma of human carcinomas, and their presence in large numbers is often
associated with the development of high-grade malignancies and poor prognoses. Moreover, in human
tumourxenograftmodels, CAFs extracted fromthe tumour aremore capableof promoting tumourgrowth
through their interactions with carcinoma cells when compared to those isolated from non-cancerous
stroma. Taken together, these observations strongly suggest that CAFs actively contribute to tumour pro-
gression. In this review we highlight the emerging roles of these cells in promoting tumourigenesis, and
we discuss themolecular mechanisms underlying their tumour-promoting capabilities and their cellular
origin.
© 2009 Elsevier Ltd. 
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. Introduction
It has long been established that cancer consists of transformed
ells that harbour genetic and/or epigenetic aberrances in onco-
enes and/or tumour suppressor genes. Accumulation of these
lterations can endow carcinoma cells with greater proliferative,
nvasive and survival propensities in a cell-autonomous fashion
1]. However, it is widely recognised that in addition to carcinoma
ells, tumours contain large numbers of various non-transformed
ells and a specialised ECM which are collectively referred to as
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the stroma. The auxiliary cells found within the stroma include
ﬁbroblasts, myoﬁbroblasts, leukocytes, endothelial cells and bone
marrow-derived cells, all of which collaborate to create the com-
plexity of the tumour microenvironment.
Recent evidence also suggests that tumourigenesis is dependant
upon contextual signals received from the closely apposed tumour-
associated stroma [2–8]. The stroma actively provides continuous
support to carcinoma cells throughout the different pathophysi-
ological processes that modulate tumour progression. In normal
tissue the stroma may actually act as a barrier in promoting
tumourigenesis by constraining tumour cell proliferation. During
tumourigenesis however, the stroma overtime evolves to actively
support tumour growth in response to molecular signals derived
from carcinoma cells and other host cell types.
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The development of the tumour and progression towards
dvanced stages of the disease requires the successful co-evolution
f both cancer cells and stromal cells. Within the tumour, the nor-
al architecture of the tissue becomes disordered and the ECM
s remodelled by mesenchymal cells such as myoﬁbroblasts found
ithin the stroma.
Myoﬁbroblasts express characteristics common to smoothmus-
le cells and pericytes and are the main cell population found in
AFs. Stromal ﬁbroblasts exposed to medium that has been con-
itioned by carcinoma cells can differentiate into myoﬁbroblasts,
nd are more competent in promoting tumour growth [9–11]. It is
ikely that carcinoma cells not only initiate the conversion of stro-
al ﬁbroblasts into myoﬁbroblasts but also help to maintain their
ctivated phenotype in vivo. The presence of myoﬁbroblastic CAFs
ithin the carcinoma can corroborate the evolution of the normal
troma towards a tumour-promoting microenvironment.
. Myoﬁbroblasts, a hallmark of activated ﬁbroblasts, in
romoting tumourigenesis
Myoﬁbroblastswere initially identiﬁed by Gabbiani et al. [12] in
ranulation tissue during wound healing. The physiological roles
f myoﬁbroblasts during wound healing have been extensively
tudied. These cells express stress ﬁbres that aid healing by con-
racting thewound, bringing the edges of the damaged tissue closer
ogether. They also stimulate angiogenesis andepithelial growthby
ncreasing their deposition of ECM proteins and secreting various
rowth factors and cytokines [8,13,14]. Whilst the wound-healing
rocess is normally complete after the ﬁrst few weeks following
njury, an inappropriate repair program is chronically sustained in
athological, ﬁbrotic diseases, such as hypertrophic scars, keloids,
cleroderma, rheumatoid arthritis and idiopathic tissue ﬁbroses.
mportantly,myoﬁbroblasts extracted frompatients suffering from
hese diseases stably maintain a transforming growth factor-
TGF-) autocrine signalling pathway, which continues to medi-
te their activated ﬁbroblastic properties during propagation in
itro [15–17]. The stability of such autocrine signallingmay be pro-
rammed by the improper tissue repair response that is constantly
ig. 1. Large numbers of myoﬁbroblasts exist in the stroma of human breast tumour. Par
nvasive breast cancer tissue (b and d) dissected from the same individual. These sections
n anti--SMA antibody (a and b). -SMA-positive myoepithelial cells surrounding epith
yoﬁbroblasts (arrows in b) are only found in the tumour-associated stroma (b) (from Rlopmental Biology 21 (2010) 19–25
activated in these diseases although this molecular mechanism is
poorly understood.
Myoﬁbroblasts derived from ﬁbrotic tissues are more capable
of promoting tumourigenesis through their interaction with carci-
noma cells compared with control ﬁbroblasts derived from normal
tissues.Activatedﬁbroblasts extracted fromthe inﬂamedsynovium
of a rheumatoid arthritis patient, when injected along with human
breast cancer cells into a recipient mouse, promote carcinoma
growth by elevating the expression of cyclooxygenase-2 (COX-2)
by carcinoma cells, an enzyme responsible for inﬂammation-
associated tumourigenesis [18].
Several animal models provide evidence that ﬁbrotic and
wounded tissues have the potential to develop into a tumour,
suggesting the presence of precursory oncogenic factors in both
afﬂicted tissues. In an avian model, Rous sarcoma virus (RSV)-
infected chickens develop sarcomas at the site of wounding
through the subsequent inﬂammatory response [19]. The loss of
Notch 1 expression within the epidermis of a conditional Notch
1ﬂox/ﬂox mouse causes a wound-like microenvironment which
consists of inﬁltrating myoﬁbroblasts and leukocytes. These cells
produce elevated levels of TGF-, keratinocyte growth factor (KGF),
and stromal cell-derived factor 1 (SDF-1: also called CXCL12) [20].
This altered microenvironment, rich in such growth factors and
cytokines, potentially promotes chemical carcinogen-induced skin
tumourigenesis of Notch 1-expressing keratinocytes in a non-cell-
autonomous manner. This study therefore indicates the inherent
tumour-suppressive role of stromal Notch signalling in maintain-
ing tissue integrity and homeostasis within the skin. Collectively,
these ﬁndings illustrate that the altered tissue microenvironment,
elicited by wounding and ﬁbrosis, can facilitate tumour incidence
and progression.
Myoﬁbroblasts are frequently observed in the stroma of
various types of human carcinomas including breast (Fig. 1)
[21,22]. Previous studies demonstrate that stromal myoﬁbrob-
lasts within the tumour resemble those present in wounded
and ﬁbrotic tissues [23–25]. Patients whose carcinomas
exhibit a greater myoﬁbroblastic stromal reaction resulting
in a so-called “desmoplastic stroma”, usually develop higher-
afﬁn sections were prepared from human non-neoplastic breast tissue (a and c) or
were stained with hematoxylin and eosin (H&E) (c and d) or immunostained with
elial cells (an arrow in a) are observed in normal tissue (a), whilst -SMA-positive
ef. [22]).
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rade malignancies associated with poor prognostic outcome
11,26,27].
CAFs have been extracted from a number of different types
f human carcinomas including breast, prostate, ovary, pancreas,
kin, colon and esophagus [22,28–33]. DNA microarray analyses,
sing either cultured CAFs or tumour-associated stromal tissues
icrodissected from the regions adjacent to human carcinoma
ells, show gene expression proﬁles distinct to those in their con-
rol groups [34–37]. CAFs isolated from different sample sets show
ifferences in the expression of large varieties of genes encod-
ng for a number of cytokines, growth factors, enzymes, ECM and
uscle-related proteins. These differences may result from dis-
rete alterations in different signalling pathways within CAFs that
egulate their phenotype and have been modiﬁed through their
nteractions with carcinoma cells.
The ability of tumour stromal ﬁbroblasts to promote carcino-
enesis was investigated using a tumour xenograft model in
hich tumour cells were implanted into immunodeﬁcient mice,
long with CAFs, counterpart ﬁbroblasts extracted from the non-
ancerous tissue in the same individual, or normal ﬁbroblasts
xtracted from healthy donors [18,22,28,29,33]. Those tumours
hat developed from carcinoma cells injected with CAFs show a
aster growth rate, compared to those tumours admixedwith either
f the control sets of ﬁbroblasts. Considerable numbers of CAFs or
ontrol ﬁbroblasts can be observed alongside carcinoma cells in
dvanced tumour xenografts [22,38]. CAF-secreted paracrine fac-
ors likely act upon these cancer cells and encourage carcinoma
rowth during tumour development.
CAFs secrete elevated levels of the cytokine SDF-1 that stim-
lates carcinoma cell proliferation in vivo, acting through the
XCR4 receptor expressed on the surface of carcinoma cells [22,39].
ther studies have also shown that CAFs secrete high levels of
GF-1 that increases CXCR4 expression on human prostate pre-
eoplastic cells [39–41]. These studies highlight the importance
f stroma-derived SDF-1/CXCR4 and TGF- paracrine signalling in
romoting tumourigenesis. Understanding themolecular crosstalk
hich occurs between CAFs and carcinoma cells is essential and
ay in the future provide novel therapeutic targets for the treat-
ent of cancer.
Myoﬁbroblasts derived from both tumour and ﬁbrotic tissues
hare similar molecular and cellular traits. The cellular processes
hat occurwithin both the tumour and the diseased tissues are per-
aps best epitomised by the statement that “tumours are wounds
hat do not heal” [23–25].
TGF- autocrine signalling plays a central role in forming and
aintaining the myoﬁbroblastic phenotype of cells involved in
brosis. However, it is unclear if such a TGF- autocrine sig-
alling pathway is also responsible formediating this phenotype in
umour-associated myoﬁbroblasts, and if these cells possess spe-
iﬁc genetic alteration(s) that are not shared with those present in
brotic tissue. This issue warrants further consideration and will
e addressed in the following section.
. Somatic genetic and epigenetic alterations in
umour-associated stromal cells
In human epithelial carcinomas, cellular transformation results
rom genetic aberrances that lead to tumour development
nd progression. Although it is now widely accepted that
umour-associated stromal cells can inﬂuence tumourigenesis, the
echanism(s) by which they acquire these tumour-promoting
roperties are not known. The presence of somatic genetic alter-
tions observed in tumour-associated stromal cells has been
ontroversial [5,42,43], and the functional relevance of these pro-
osed alterations to their phenotypes remains unclear.lopmental Biology 21 (2010) 19–25 21
Genetic alterations, such as chromosomal loss of heterozygos-
ity (LOH) and somatic mutations, have been reported in stromal
regions microdissected from various human carcinomas includ-
ing those of breast [44–47], ovarian [48], colon [45], bladder [49],
and head and neck [50]. Indeed, analyses performed on microdis-
sected regions of stromal tissues from within the tumour identify
somatic TP53 mutations within 25.6% of the hereditary group, and
19.4% of the sporadic group of breast cancer patients [47]. There
is also a higher risk of regional lymph node metastases occurring
in these patients. Moreover, tumour-associated stromal regions
microdissected from prostate tumours, when raised in epithe-
lial cell-speciﬁc oncogene-driven transgenic mice with a TP53+/−
background, display frequent loss of the wild type TP53 allele [51].
A complementary study ﬁnds that, when human breast carcinoma
cells are implanted into p53+/− recipient mice, the host stromal
cells isolated from the developing tumour lose their wild type TP53
allele resulting in p53−/− tumour-associated stromal cells [52].
Although loss of p53 activity within stromal cells appears
instrumental in the development of a tumour-promoting stroma,
it is unclear if this can trigger the differentiation of ﬁbroblasts
and/or progenitor cells intomyoﬁbroblasts. Furthermore, although
aberrations in p53 signalling are often associated with a higher
incidence of mesenchymal tumours in patients with Li–Fraumeni
syndrome and in p53-mutant mice, it is unclear why carcinosar-
comas, which are malignant biphasic epithelial and mesenchymal
tumours, very rarely (∼0.2%) develop in human breast carcinoma
patients [53,54].
The above studies detected genetic alterations within the
stroma of parafﬁn-ﬁxed tumour tissues. Conversely, genome-wide
genetic analyses, including single nucleotide polymorphism (SNP)
and comparative genomic hybridisation (CGH) arrays using freshly
frozen tissues, fail to detect any such signiﬁcant somatic genetic
alterations within the stroma of human breast tumours. This is
highlighted in one important study that detected a LOH event on
chromosome 22 in only 1 out of 35 human breast and ovarian
carcinoma-associated stroma samples [55].
Speciﬁcally in CAFs, such analyses have also failed to detect
substantial genetic alterations [34,55,56]. Our own observations
indicate that CAFs themselves are non-neoplastic as they typically
senesce in vitro, and show no detectable chromosomal abnormal-
ities and no cellular phenotypes characteristic of malignant cell
types [22]. Nonetheless, there is a possibility that only a small num-
ber of CAFs may actually possess genetic alterations, and these
cells may be difﬁcult to detect in a large heterogenous ﬁbroblast
population. Other studies, however, have reported the presence
of epigenetic modiﬁcations, such as DNA methylation within the
genome of CAFs thatmay give rise to their tumour-promoting phe-
notype [57,58].
The biological relevance of genetic and/or epigenetic alterations
within the tumour stroma and the cellular and molecular mecha-
nisms that underlie the tumour-promotingphenotype of CAFs have
yet to be elucidated. The detection of somatic alterations in some
studies, whilst not in others, may be in part due to the different
methods used to acquire and prepare tissues for analysis, the use
of parafﬁn-ﬁxed tissues instead of frozen tissues, or the different
types of genomic analyses performed. Future independent analyses
are required in order to clarify these issues.
4. Heterogeneity of tumour stromal ﬁbroblastsWithin a murine renal ﬁbrosis model, signiﬁcant numbers of
myoﬁbroblasts found in affected tissues are derived from epithe-
lial cells, endothelial cells and circulating bone marrow cells
[59]. In tumour tissue, myoﬁbroblasts are also proposed to orig-
inate from different cell types including pre-existing ﬁbroblasts,
22 M. Shimoda et al. / Seminars in Cell & Developmental Biology 21 (2010) 19–25
Fig. 2. Four alternative models for cellular origins and evolution of myoﬁbroblasts in the stroma of tumour. (1) Transdifferentiation into myoﬁbroblasts. Populations of
residual mesenchymal cells (e.g., stromal ﬁbroblasts) might transdifferentiate into myoﬁbroblasts without acquiring any signiﬁcant genetic alterations; (2) differentiation
into myoﬁbroblasts. Stromal myoﬁbroblasts are recruited from specialised circulating bone marrow-derived progenitor cell types, such as ﬁbrocytes and MSCs, which
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xpanded in the tumour without acquiring any further phenotypic alterations; (4) s
ay allow for the clonal selection from a small population of ﬁbroblasts or progeni
ifferentiate into myoﬁbroblasts.
readipocytes, smooth muscle cells, endothelial cells, epithelial
ells andbonemarrow-derivedprogenitors [60–65]. Bonemarrow-
erived cells are a signiﬁcant cellular source of myoﬁbroblasts
ound in the tumour stroma. Nearly 40% of the total stromal myoﬁ-
roblast population within the tumour, 28 days after implantation
f pancreatic carcinoma cells, is shown as bonemarrow-derived in
ne tumour xenograft murine model [60], and approximately 25%
n 16–18-week-old pancreatic tumours, spontaneously arising in
nother transgenic mouse model [61].
Whilst epithelial cells are the major cellular origin of activated
broblasts during ﬁbrosis, it is unclear if normal or malignant
pithelial cells convert into myoﬁbroblasts in tumour. The tumour
icroenvironment is rich in the cytokine TGF-. In vitro studies
ave shown that ﬁbroblasts cultured in the presence of TGF-
ost often undergo transdifferentiation into myoﬁbroblasts. This
upports the notion that myoﬁbroblast differentiation of residual
broblastsmay also occurwithin the stroma of tumour in response
o TGF- paracrine signalling, although this has yet to be proven.
In 2006 we proposed three tentative models for the origins of
AFmyoﬁbroblasts within the tumour [6]. In light of recent studies
nd emerging data, we have now revised our models as illus-
rated in Fig. 2; (1) populations of residual mesenchymal cells (e.g.,
tromal ﬁbroblasts) might transdifferentiate into myoﬁbroblasts
ithout the acquisition of any genetic alterations, thus mimick-
ng the scenario that occurs during wound healing. Myoﬁbroblasts
ound within the tumour are therefore essentially the same as
yoﬁbroblasts involved in wound healing and ﬁbrosis; (2) spe-
ialised circulating progenitor cell types, such as ﬁbrocytes and
esenchymal stem cells (MSCs), are recruited into the tumour
troma where they are able to differentiate into myoﬁbroblasts.
hese ﬁrst two models suggest that tumour-induced education of
he nearby stromal cells occurs through myoﬁbroblast differenti-
tion; (3) a rare population of pre-existing myoﬁbroblasts may bemyoﬁbroblasts. A small population of pre-existing myoﬁbroblasts may be clonally
n of genetically altered ﬁbroblasts. Acquisition of genetic alterations (e.g., p53 loss)
at have undergone such alterations. The resulting ﬁbroblasts may or may not then
clonally expanded in the tumour but do not acquire any additional
alterations; (4) acquisition of genetic alterations (e.g., p53 loss)
within a small population of ﬁbroblasts and/or progenitors may
allow for their clonal selection and expansion. Such genetic alter-
ationsmay ormay not be relevant tomyoﬁbroblast differentiation.
These last two models effectively rely upon the clonal selection of
a small number of altered stromal cells.
5. The role of tumour stromal ﬁbroblasts in promoting
tumour progression
5.1. Tumour stromal ﬁbroblasts boost neoangiogenesis
In cancer neoangiogenesis is a pathophysiological process
essential for the growth and progression of a tumour. The process
of neoangiogenesis is facilitated through the increased expression
of various growth factors, cytokines and ECMproteins produced by
tumour-associated stromal cells (Fig. 3).
Elevated levels of the proangiogenic chemokine SDF-1 are
secreted by stromal ﬁbroblasts found in human breast and
prostate carcinomas [22,34,39,66]. SDF-1 boosts neoangiogenesis
by recruiting endothelial progenitor cells (EPCs) into the tumour
[22]. Moreover, elevated levels of CXCL14 expression are detected
in mammary tumour stromal ﬁbroblasts and in tumour stromal
regions microdissected from human prostate cancers [34,67]. The
cognate receptor for this ligand has not yet been identiﬁed. How-
ever, forced expression of CXCL14 in ﬁbroblasts, injected into
a murine xenograft model along with prostate carcinoma cells,
enhances neoangiogenesis within the tumour [67].
A recent report suggests that tumour stromal ﬁbroblasts also
mediate resistance to anti-angiogenic therapy. In a murine model,
ﬁbroblast-enriched cell fractions, extracted from refractory lym-
phomas resistant to anti-VEGF antibody treatment, upregulate
M. Shimoda et al. / Seminars in Cell & Developmental Biology 21 (2010) 19–25 23
Fig. 3. Diverse tumour-promoting affects of CAFs. Carcinoma cell-derived TGF- and PDGFs play central role to induce and maintain CAF myoﬁbroblasts within the stroma
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roliferation. Moreover, CAFs enhance tumour invasion through their secretion of T
urthermore, CAF-produced SFRP1 [78] serves as an anti-apoptotic factor. Taken to
o produce elevated levels of various growth factors, cytokines, ECM proteins and M
heir levels of PDGF-C mRNA expression by 200-fold compared to
broblasts isolated from non-refractory tumours. The authors con-
lude that the elevated levels of PDGF-C in ﬁbroblasts expressed
n the therapy-resistant tumours directly promote neoangiogene-
is [68]. In a transgenic mouse model for cervical squamous cell
arcinoma induced by infection with human papilloma virus, type
6 E6/E7, stromal PDGF receptor signalling is inhibited by treat-
ent with a speciﬁc kinase inhibitor. As a result, tumour growth
nd neoangiogenesis are signiﬁcantly inhibited through attenua-
ion of FGF2 and FGF7 expression in tumour stromal ﬁbroblasts,
ighlighting the importance of stromal PDGF receptor signalling in
romoting neoangiogenesis [69]. Collectively, these ﬁndings high-
ight the important role of tumour stromal ﬁbroblasts in promoting
eoangiogenesis throughsecretionofvarious cytokinesandgrowth
actors.
.2. Tumour stromal ﬁbroblasts promote tumour cell invasion
The tumour invasion-metastasis cascade is a complex mul-
istep process that allows tumour cells to escape the primary
umour mass and colonise distant organs and tissues. The cascade
onsists of a series of distinct processes which include localised
nvasion, entrance into the systemic circulation, survival during
ransportation, extravasation, the establishment of micrometas-
ases in distal tissues and colonisation resulting in the formation
f macroscopic metastases [70]. It has long been assumed that dis-
emination of metastatic carcinoma cells depends largely on their
ell-autonomous effects in response to genetic and/or epigenetic
lterations that accumulate within them. However, emerging evi-
ence now proposes an additional schema that the interaction
f tumour-associated stroma with carcinoma cells facilitates the
nvasion-metastasis cascade [71].
As previously mentioned, the presence of larger numbers of
yoﬁbroblasts in the stroma of different human cancers is asso-
iated with an increased risk of invasion and metastasis and a
oor clinical prognosis [26,27,72]. Human colorectal carcinoma
ells that interact with stromal cells at the invasive front also
ncrease their expression of nuclear -catenin which can acti-
ate Wnt signalling in these cells [73]. Moreover, tumour stromal
broblasts extracted fromhuman colon adenocarcinomas andTGF-
-primed stromal ﬁbroblasts upregulate expression of tenascin-C2], IGF2 [76], HGF [77], Gremlin-1 [30], and SFRP-1 [78] also stimulate tumour cell
tenascin-C [31], tenascin-W [79], HGF [31], andmatrix metalloproteinases (MMPs).
r, CAFs could promote tumour progression in several aspects through their ability
andHGF, both ofwhich co-operate to promote the invasive propen-
sity of human colon carcinoma cells within a collagen gel matrix
[31].
Interestingly, higher levels of cytokines, such as TGF-, a crit-
ical mediator of the epithelial-to-mesenchymal transition (EMT),
are often produced by the tumour-associated stroma [74]. It is
therefore possible that the activated stroma contributes to induc-
tion of EMT in nearby carcinoma cells, although at present little is
known about the affects of the stroma upon EMT and the invasion-
metastasis cascade.
6. Perspective
In cancer the stroma is able to facilitate disease progression
through its interactionwith carcinoma cells.Whilst CAFs undoubt-
edly contribute to tumourigenesis, more research is required in
order to shed light on their molecular interactions with carcinoma
cells and to further understand the stromal signalling pathways
that are actively involved.
As neoplastic cells evolve into a more malignant cell popula-
tion during tumour progression, tumour-associated stromal cells
may evolve alongside them supporting their phenotypic conver-
sion throughout the disease process. Moreover, CAF paracrine
signalling may act upon cancer cells, facilitating their invasion into
healthy tissue and their subsequent colonisation of distal organs
and tissues. Further research is therefore required in order to fully
understand the molecular mechanisms underlying the potential
role of CAFs in promoting invasion and metastasis. It is also nec-
essary to investigate how CAFs retain their ability to promote
carcinoma growth in a cell-autonomous fashion, and if particu-
lar somatic genetic alteration(s) not only are responsible for the
maintenance of this stable phenotype but also mediate the differ-
entiation of cells into myoﬁbroblasts.
Future research will focus on identifying the selective pres-
sures and determining the cellular and molecular mechanisms
which drive forward the evolution of the tumour-promoting
stroma. Delineating the molecular crosstalk between stromal cells
and carcinoma cells may provide invaluable insights into the
pathophysiological processes involved in cancer. The develop-
ment of new mouse models, multiscale mathematical models,
improved in vivo imaging techniques and the identiﬁcation of
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ions will further our understanding of cancer in the future. Such
dvancements in research may lead to the development of novel
herapeutic approaches to treating cancer by targeting the inter-
ctions between the stroma and carcinoma cells that mediate
umourigenesis.
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